VBI Vaccines Inc. (NASDAQ:VBIV) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $704.33 thousand.
VBI Vaccines Inc. (NASDAQ:VBIV) reported Q2 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $300 thousand versus the consensus estimate of $704.33 thousand.